Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) traded up 8% during mid-day trading on Monday . The stock traded as high as $7.82 and last traded at $7.41, with a volume of 1,510,402 shares trading hands. The stock had previously closed at $6.86.

Several analysts have issued reports on the company. Zacks Investment Research upgraded Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 target price on the stock in a research note on Tuesday, May 31st. Maxim Group restated a “buy” rating and issued a $15.00 target price on shares of Anavex Life Sciences Corp. in a research note on Wednesday, May 11th. Finally, FBR & Co reiterated a “buy” rating on shares of Anavex Life Sciences Corp. in a research note on Wednesday, June 22nd.

The stock’s 50 day moving average price is $5.55 and its 200-day moving average price is $4.86. The company’s market cap is $266.40 million.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last posted its quarterly earnings results on Wednesday, May 11th. The company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.10. Equities research analysts anticipate that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.